Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Dizal (Jiangsu) Pharmaceutical developed Sunvozertinib (DZD9008), a selective EGFR tyrosine kinase inhibitor, to treat metastatic NSCLC patients with EGFR exon 20 insertion mutations—an area with limited treatment options. To secure accelerated FDA approval, Dizal partnered with Certara to address PK variability, define exposure–response (E-R) relationships, and support global regulatory submissions under tight timelines.

Certara built a population PK model for Sunvozertinib and its metabolite, performed E-R analyses linking exposure to efficacy and safety, and delivered regulatory-ready reports. This collaboration streamlined submissions, informed dose selection, and helped achieve accelerated approval, bringing a needed oral therapy to patients faster.

服务

Pharmacometrics, Clinical Pharmacology and Translational Medicine, Drug Development Services, Modeling and Simulation Services

解决方案

Early Clinical, Late Clinical, Regulatory

治疗领域

肿瘤学

The challenge

Dizal (Jiangsu) Pharmaceutical was developing Sunvozertinib (DZD9008), a selective EGFR tyrosinekinase inhibitor, to address a critical unmet need inpatients with metastatic NSCLC harboring EGFR exon20 insertion mutations.

Existing treatments had limited benefit and hightoxicity, making it vital to clearly demonstrate benefit-risk to regulators. To secure accelerated FDA approval, Dizal needed to:

Build a robust understanding of Sunvozertinib andits metabolite DZ0753.
Identify key sources of PK variability acrossdiverse patients.
Define exposure–response (E-R) relationships forefficacy and safety.
Navigate complex global regulatory submissionsunder tight timelines.

The solution

Dizal partnered with Certara to leverage expertise inpharmacometrics and regulatory strategy.

Certara delivered comprehensive modeling andanalysis, including:

Joint Population PK Model: Built a semi-mechanistic, two-compartment modeldescribing the PK of Sunvozertinib and itsmetabolite DZ0753 across healthy volunteersand NSCLC patients.
Exposure–Response (E-R) Analysis: Linkedsunvozertinib exposure to efficacy (objectiveresponse rate) and safety outcomes, includingkey adverse events such as diarrhea, rash, anddose-limiting toxicities.
Regulatory-Ready Deliverables: Providedvalidated reports and simulations quantifyingvariability across patient factors like age, bodyweight, and organ function to support globalsubmissions.

The impact

Through this collaboration, Dizal successfully:

Justified the benefit-risk profile ofSunvozertinib, supporting its selection as theoptimal therapy for patients with EGFR exon20 insertion mutations.
Streamlined regulatory submissions withclear, validated population PK and E-Ranalyses.
Enabled data-driven dose selection forcurrent and future studies, reducing the needfor unnecessary clinical trials.
Achieved accelerated FDA approval, bringing alife-changing oral therapy to patients fasterthan traditional development timelines.

“Sunvozertinib received accelerated FDA approval for metastatic NSCLC with EGFR exon 20 insertion mutations — a milestone achieved through exceptional collaboration.”

Kan Chen, Vice President of Clinical Pharmacology, Dizal (Jiangsu) Pharmaceutical

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

The challenge

The solution

The impact

联系 Certara

精选推荐

订阅时事通讯

快捷链接

解决方案

联系我们

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

The challenge

The solution

The impact

联系 Certara

精选推荐

肿瘤领域模型引导的药物开发（MIDD）精要

基于 MIDD 重塑监管策略：《ICH M15 指南草案》深度剖析

Phoenix NLME & Pirana 双擎驱动：群体 PK 建模高效精准实战解析 [亚太地区网络研讨会]

订阅时事通讯

快捷链接

解决方案

联系我们